Emerging Treatment Options for Patients with NSCLC with ALK Rearrangements
Experts on non–small cell lung cancer discuss recent data on brigatinib and lorlatinib for the treatment of patients with ALK rearrangements.
Source: onclive.com
Stay updated with breaking news from Alta 1l. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Experts on non–small cell lung cancer discuss recent data on brigatinib and lorlatinib for the treatment of patients with ALK rearrangements.